- RSS Channel Showcase 4322074
- RSS Channel Showcase 7166399
- RSS Channel Showcase 2520354
- RSS Channel Showcase 2515981
Articles on this Page
- 08/22/17--06:15: _Federal Court of Ap...
- 10/24/17--06:41: _Federal Court Adjou...
- 10/31/17--06:28: _Federal Court Affir...
- 11/14/17--06:23: _Federal Court finds...
- 12/12/17--06:23: _Federal Court shoot...
- 12/19/17--06:34: _Federal Court Uphol...
- 01/16/18--06:21: _Federal Court Rejec...
- 04/03/18--06:25: _Non-Infringing Alte...
- 10/24/17--06:41: Federal Court Adjourns Motion for Confidentiality Order
- 10/31/17--06:28: Federal Court Affirms Price Regulation Schemes are intra vires
2016 FCA 161 - The FCA remitted a proceeding back to the FC for redetermination after agreeing with Pfizer that part of Teva’s evidence in the FC decision was based on hearsay.
The post Federal Court of Appeal remits decision based on hearsay evidence back to the Federal Court for redetermination appeared first on PCK.
2017 FC 548 - In this application for judicial review over s. 5 of the PM(NOC) Regulations, the FC agreed with the AG who argued that since another innovator also had patents listed on the Patent Register pertaining to products to which Innovator Company made comparisons, the other innovator was a necessary respondent to the application.
The post Federal Court Adjourns Motion for Confidentiality Order appeared first on PCK.
2016 FC 716 - The AG was successful in bringing a motion to strike Alexion's constitutional challenge to the patented medicines price regulation scheme in the Patent Act. The motion was brought on the ground that the application was bereft of any chance in light of a line of jurisprudence, which had fully and finally determined that these sanctions are intra vires and constitutional.
The post Federal Court Affirms Price Regulation Schemes are intra vires appeared first on PCK.
2016 FC 1362 - The formulation patent for the insomnia-treating drug zolpidem was found to be substantially valid, but not infringed by Pharmascience's generic version of zolpidem.
The post Federal Court finds Insomnia-treating Drug Patent neither Invalid nor Infringed appeared first on PCK.
2017 FC 774 - The FC granted Pfizer's order pursuant to Section 6 of the PM(NOC) Regulations, prohibiting the Minister of Health from issuing a NOC to Apotex, with respect to a Canadian patent The FC found, on a balance of probabilities, that Apotex’s allegations of obviousness, inutility, non-infringement, overpromising, anticipation and double patenting were not justified.
The post Federal Court shoots down an attempted revival of the promise doctrine appeared first on PCK.
2017 FC 777 - The FC rejected Teva’s allegations that Pfizer's Canadian patent was obvious and lacked utility. The FC found that the POSITA would not have been able to predict the novel crystalline form taught by the patent, and that the subject-matter of the invention claimed in the patent was useful.
The post Federal Court Upholds Pfizer’s Polymorph Patent for the Depression Drug PRISTIQ as Inventive and Useful appeared first on PCK.
2017 FC 857 - The Federal Court upheld the Minister of Health’s decision to cancel reconsideration for Apo-Omeprazole Magnesium Tablets manufactured by Apotex Inc. This is yet another failed attempt by Apotex to obtain approval for the magnesium tablet form of its anti-ulcer drug.
The post Federal Court Rejects Apotex’s Judicial Review Application for Apo-Omeprazole Magnesium Tablets appeared first on PCK.
2017 FC 726 - The FC held that Apotex did not satisfy the factual burden required to establish a hypothetically viable non-infringing substitute during the period of infringement, which could reduce the infringement profits owed to AstraZeneca.
The post Non-Infringing Alternative Defence Denied in Omeprazole Infringement Profit Case appeared first on PCK.